Key result
Cilostazol significantly improved the ankle-brachial index (from 0.84 to 0.89, P<0.001) and increased plasma sRAGE levels over 52 weeks in patients with type 2 diabetes and peripheral arterial occlusive disease.
Why the study?
Does cilostazol improve ankle-brachial index and sRAGE levels in patients with type 2 diabetes and peripheral arterial occlusive disease?
Population
90 adults with type 2 diabetes and peripheral arterial occlusive disease defined as intermittent…
Comparison
Cilostazol 100 mg oral twice daily for 52 weeks vs Placebo for 52 weeks
Design
RCT, 1:1 randomization, open-labeled, placebo-controlled
Follow-up
52 weeks
Authors
Loading...
Hypothesis-generating for cilostazol augmentation of sRAGE in diabetic PAOD; randomized trials needed before clinical adoption.
RCT (n=90)
Open-label
1:1
No
Does cilostazol improve ankle-brachial index and sRAGE levels in patients with type 2 diabetes and peripheral arterial occlusive disease?
Absolute Event Rate: 0.89% vs 0.83%
p-value: p=<0.001
Cilostazol improves ankle-brachial index and increases plasma sRAGE levels in patients with type 2 diabetes and peripheral arterial occlusive disease, suggesting a potential mechanism for its vascular benefits.
Liu et al. (2015) conducted an RCT in Type 2 diabetes with peripheral arterial occlusive disease (PAOD) (n=90). Cilostazol vs. Placebo was evaluated on Change in ankle-brachial index (ABI) after 52 weeks (p=<0.001). Cilostazol significantly improved the ankle-brachial index (from 0.84 to 0.89, P<0.001) and increased plasma sRAGE levels over 52 weeks in patients with type 2 diabetes and peripheral arterial occlusive disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: